Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease
Open Access
- 20 May 2020
- journal article
- research article
- Published by Wiley in ESC Heart Failure
- Vol. 7 (4), 1605-1614
- https://doi.org/10.1002/ehf2.12712
Abstract
Aims Right ventricular hypertrophy (RVH) is a common finding in Anderson–Fabry disease (AFD), but the prognostic role of right ventricular (RV) involvement has never been assessed. The aim of our study was to evaluate the prognostic significance of RVH and RV systolic function in AFD. Methods and results Forty‐five AFD patients (56% male patients) with extensive baseline evaluation, including assessment of RVH and RV systolic function, were followed‐up for an average of 51.2 ± 11.4 months. RV systolic function was assessed by standard and tissue Doppler echocardiography. Cardiovascular events were defined as new‐onset atrial fibrillation (AF), sustained ventricular arrhythmias, heart failure, or pacemaker/implantable cardioverter defibrillator implantation; renal events were defined as progression to dialysis and/or renal transplantation or significant worsening of glomerular filtration rate; and cerebrovascular events were defined as transient ischaemic attack or stroke. Fourteen patients (31.1%) presented RVH, while RV systolic function was normal in all cases. During the follow‐up period, 13 patients (28.8%, 11 male) experienced 18 major events, including two deaths. Cardiovascular events occurred in eight patients (17.7%). The most common event was pacemaker/implantable cardioverter defibrillator implantation (six patients, 13.3%), followed by AF (three cases, 6.6%). Only one case of worsening New York Heart Association class (from II to III and IV) was observed. Ischaemic stroke occurred in three cases (6.6%). Renal events were recorded in three patients (6.6%). At univariate analysis, several variables were associated with the occurrence of events, including RVH (HR: 7.09, 95% CI: 2.17 to 23.14, P = 0.001) and indexes of RV systolic function (tricuspid annular plane systolic excursion HR: 0.77, 95% CI: 0.62 to 0.96, P = 0.02; and RV tissue Doppler systolic velocity HR: 0.76, 95% CI: 0.61 to 0.93, P = 0.01). At multivariate analysis, proteinuria (HR:8.3, 95% CI: 2.88 to 23.87, P < 0.001) and left ventricular mass index (HR: 1.02, 95% CI: 1.00 to 1.03, P = 0.03) emerged as the only independent predictors of outcome. Conclusions RVH and RV systolic function show significant association with clinical events in AFD, but only proteinuria and left ventricular mass index emerged as independent predictors of outcome. Our findings suggest that RV involvement does not influence prognosis in AFD and confirm that renal involvement and left ventricular hypertrophy are the main determinant of major cardiac and non‐cardiac events.Keywords
This publication has 33 references indexed in Scilit:
- Long‐term outcome of enzyme‐replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 2013
- Cardiovascular Events in Patients With Fabry Disease: Natural History Data From the Fabry RegistryJournal of the American College of Cardiology, 2011
- The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapyHeart, 2010
- Guidelines for the Echocardiographic Assessment of the Right Heart in Adults: A Report from the American Society of Echocardiography: Endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of EchocardiographyJournal of the American Society of Echocardiography, 2010
- The heart in Anderson-Fabry disease and other lysosomal storage disordersHeart, 2007
- Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome surveyEuropean Heart Journal, 2007
- Two‐Dimensional Assessment of Right Ventricular Function: An Echocardiographic–MRI Correlative StudyEchocardiography, 2007
- The right ventricle in Fabry diseaseActa Paediatrica, 2005
- The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapyClinical Genetics, 2004
- Early Detection of Fabry Cardiomyopathy by Tissue Doppler ImagingCirculation, 2003